Ophtholic Ultra; Ophtholic Ultra
A Single-Center, Prospective, Randomized, Controlled, Assessor-Blinded Study Evaluating the Efficacy and Safety of Ophtholic Ultra Ophthalmic Lubricating Solution for the Prevention and Correction of Ocular Surface Disorders After Uncomplicated Cataract Surgery
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Исследование идёт.
- Возраст участников: 50–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановое окончание — 11.2026.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 1 · невключение: 3
Критерии включения
- 1\. Age 50 to 70 years, inclusive. 2. Age-related cataract with a clinical indication for planned phacoemulsification with intraocular lens implantation. 3. Ability to understand the study information and provide written informed consent. 4. Willingness and ability to comply with the scheduled study visits and study procedures. 5. Ocular surface symptoms, including burning, dryness, tearing, frequent blinking, or foreign body sensation. 6. Corneal transparency sufficient to perform tear film break-up time assessment and fluorescein staining. 7. Uncomplicated cataract surgery completed without complications requiring a change in standard postoperative management.
Критерии невключения
- 1\. Active infectious or clinically significant inflammatory disease of the ocular surface, eyelids, or lacrimal system. 2. Severe dry eye disease requiring continuous anti-inflammatory, immunomodulatory, or intensive tear replacement therapy. 3. Sjögren syndrome, active systemic autoimmune disease, or another condition expected to substantially affect tear production. 4. Corneal scar, dystrophy, degeneration, marked irregularity, or neurotrophic keratopathy. 5. Significant meibomian gland dysfunction requiring immediate specialized treatment. 6. Uveitis, uncontrolled glaucoma, or previous corneal refractive or other corneal surgery within 12 months before enrollment. 7. Contact lens use within 14 days before the baseline assessment. 8. Use of artificial tears or other topical ophthalmic products affecting the ocular surface that cannot be discontinued for at least 24 hours before baseline testing. 9. Known allergy or hypersensitivity to any component of Ophtholic® Ultra or fluorescein. 10. Any serious medical or cognitive condition that, in the investigator's opinion, makes participation unsafe or prevents reliable study data collection.
- Exclusion Criteria Before Randomization
- 1\. Intraoperative posterior capsule rupture, significant vitreous loss, inability to implant the planned intraocular lens, or another significant intraoperative complication. 2. Need for additional surgical intervention or a change in the standard postoperative eye drop regimen that substantially differs from the study protocol. 3. Withdrawal of informed consent before randomization.
Источник: ClinicalTrials.gov, NCT07868965 · запись обновлена в реестре 9 октября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 7
- Change in tear film break-up time (TBUT) from baseline to Day 90 after cataract surgery — Baseline (Day -1) to Day 90
Цель исследования
Study of the Effectiveness and Safety of Ophtholic Ultra in Preventing and Correcting Ocular Surface Disturbances After Uncomplicated Cataract Surgery
This is a single-center, prospective, randomized, controlled, assessor-masked clinical study evaluating the effectiveness and safety of Ophtholic Ultra, a preservative-free moisturizing ophthalmic solution containing 0.2% tamarind seed polysaccharide and 0.4% sodium hyaluronate, in patients undergoing uncomplicated cataract surgery.
Cataract surgery can temporarily affect the ocular surface and tear film, leading to dry eye symptoms, discomfort, epithelial changes, and reduced tear film stability. This study will evaluate whether adding Ophtholic Ultra to standard postoperative treatment can improve ocular surface condition after cataract surgery.
Approximately 60 adults aged 50 to 70 years with age-related cataract will be randomized into three groups. One group will receive standard postoperative treatment plus Ophtholic Ultra for 3 months, the second group will receive standard postoperative treatment plus Ophtholic Ultra for 1 month, and the third group will receive standard postoperative treatment without moisturizing eye drops.
The primary outcome will be the change in tear film break-up time (TBUT) from baseline to Day 90 after cataract surgery. Secondary outcomes will include Schirmer I test results, corneal epithelial staining and defects, visual acuity, patient-reported ocular symptoms and comfort, refractive outcomes, adherence, tolerability, and adverse events.
Participants will be assessed before surgery and on Days 7, 30, and 90 after surgery.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07868965 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.